18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting

A.A Tarhini,A.C Tan,S Arnold,J Carpten,H Colman,G.J Weiner,I Puzanov,I El Naqa,M Mccarter,J.R Conejo-Garcia,V Sukrithan,W.S Dalton,S.S Coleman,P Hwu,A.P Ikeguchi,R Aakrosh,M.L Churchman

doi:10.1016/j.iotech.2022.100123

18P Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting

A.A Tarhini, A.C Tan + Show 15 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100123

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
Citations: 1	License type: cc-by-nc-nd

Affiliation: Moffitt Cancer Center, Markey Cancer Center, University of Kentucky, University of Southern California, University of Utah Hospital, University of Iowa, Roswell Park Cancer Institute, University of Colorado Denver, James Cancer Hospital, The Ohio State University, Oklahoma State University Oklahoma City, University of Oklahoma, University of Virginia

#Immune Checkpoint Inhibitors #Gene Expression Signatures + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Previous studies developed predictive biomarkers related to immune checkpoint inihibitors (ICI) based on clinical trials cohorts. Here, we leverage the ORIEN data conducted under the Total Cancer Care protocol across 18 collaborating cancer centers to evaluate the predictive value of published gene expression signatures in real-world data (RWD) of patients with cancer treated with ICI.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Immuno-Oncology and Technology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.